Mark Flory strives to effectively leverage proteomic technologies to facilitate research efforts focused on the discovery and validation of protein signatures in a variety of contexts including cancer.  Mark is currently the Director of the Knight Protein Target Identification (KPTI, KPTI.Team@ohsu.edu) OHSU Service Center that offers as a for-fee service deep discovery-mode proteomic profiling of blood and other complex biofluids using a differentiating combination of technologies including Seer Proteograph nanoparticle protein enrichment and high-sensitivity mass spectrometry.  He received his Ph.D. in molecular and cellular biology at the University of Washington and subsequently enjoyed postdoctoral training in biological mass spectrometry as a member of Ruedi Aebersold’s group at the Seattle Institute for Systems Biology.  Mark draws on his diverse experiences in applying proteomics in academia, the biotech sector, and at the Stanford University Canary Center for Cancer Early Detection in helping colleagues effectively apply proteomic methods to augment a wide variety of studies.